Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study procedures and are willing to sign a written consent form agreeing to take part.
- People who are able to follow the study schedule, including attending visits and following the treatment plan.
- People who are currently taking niraparib (either alone or with another treatment) as part of a GlaxoSmithKline/TESARO-sponsored study that has already met its main research goals.
- People whose treating doctor has assessed that they are currently benefiting from niraparib in their current study.
- People who are capable of becoming pregnant and are sexually active, along with their partners, must agree to use an effective form of contraception throughout the study and for 180 days after the last dose of the study drug.
Who may not be able to join:
- People who have already been permanently taken off niraparib in their current study, for any reason.
- People who currently have unresolved side effects that have caused their niraparib treatment to be paused in their current study (joining may be possible once those side effects have resolved and treatment can resume — confirm with trial site).
- People who are pregnant, or who plan to become pregnant during the study or within 180 days of the last dose of the study drug.
- People who are breastfeeding, or who plan to breastfeed within 30 days of the final dose of the study drug (storing breast milk for use during this period is also not permitted).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: GSK Clinical Trials, GlaxoSmithKline
Phone: 877-379-3718
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI); Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status; Number of participants with clinically significant changes in hematology and clinical chemistry parameters; Number of participants with clinically significant changes in vital signs; Number of participants with clinically significant changes in physical examination; Number of participants with use of concomitant medications
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.